Venous Thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE) is one of the most important, potentially preventable, causes of death and morbidity especially of hospitalised patients(1).
Every year it is estimated that:
- One million Europeans will suffer from VTE and one third will die (1).
- VTE kills more people in Europe than breast cancer, prostate cancer, HIV AIDS and traffic accidents combined (2).
- Deaths from VTE in the US exceed those from heart attacks and strokes (3).
- In the USA, approximately $39.9 BILLION is spent treating preventable hospital acquired VTE every year (3).
- $19.1 BILLION is spent treating the long term effects of VTE (3).
1 Cohen AT, Tapson VF, Bergman J-F et al. Venous thromboembolism and prophylaxis in the acute hospital setting (ENDORSE study): A multinational cross-sectional study. Lancet. 2008; 371: 387-394.
2 Cohen AT, Agnelli A, Anderson FA et al. Venous thromboembolism (VTE) in Europe: The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756–764.
3 Heit J, Cohen A, Anderson FJ. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood. 2005; 106: 267A.
4 Mahan CE, Borrego ME, Woershing AL et al. Venous thromboembolism: Annualised United States model for total, hospital acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012; 108(2): 291-302.